Pharvaris cuts HAE attacks 83% with oral deucrictibant XR. Can it challenge injections?
Once-daily deucrictibant XR reduced hereditary angioedema attacks by 83% across the Phase 3 CHAPTER-3 population, giving Pharvaris a potential oral prophylaxis product alongside its separately developed immediate-release rescue formulation.
